Optimind Pharma Corp. (CSE: OMND) (the “Optimind” or the “Company”) is pleased to announce that it has entered into an acquisition agreement dated October 12, 2023 (the “Agreement”) with Wolf Acquisitions 1.0 Corp. (“Wolf”), an arm’s length private British Columbia corporation, and 1443885 B.C. Ltd. (“Subco”), a wholly-owned subsidiary of the Company, pursuant to which Optimind will acquire all of the issued and outstanding common shares of Wolf (each, a “Wolf Share”) by way of “three-cornered” amalgamation (the “Transaction”).
Wolf Acquisitions 1.0 Corp.
Incorporated in February of 2021, Wolf is a private British Columbia corporation which has investments and other interests primarily focused on the psychedelic industry.
Transaction Summary
Pursuant to the Agreement, Optimind will acquire all of the issued and outstanding Wolf Shares by way of a “three-cornered” amalgamation (the “Amalgamation”) whereby Subco and Wolf shall amalgamate pursuant to the provisions of the Business Corporations Act (British Columbia) to form one corporation, which shall be a wholly owned subsidiary of the Company.
In consideration for the Wolf Shares, the Company has agreed to issue an aggregate of 45,000,000 common shares in the capital of the Company (each, a “Share”) to the Wolf shareholders. Each Share issued in connection with the Transaction will be issued at a deemed price of $0.05 per Share, reflecting a premium to the current market price.
The Transaction is subject to certain conditions, including, but not limited to: (i) the receipt of all necessary consents, waivers and approvals; (ii) the closing of the Private Placement (as described below); (iii) Wolf having at least $350,000 in cash and marketable securities and no liabilities, other than those incurred in connection with the proposed Transaction; (iv) there having been no material adverse effect occurring with respect to the Company or Wolf; and (v) other closing conditions customary for transactions of this nature.
Following the closing of the Transaction but prior to the closing of the Private Placement, Optimind is expected to have 143,091,991 Shares issued and outstanding on an undiluted basis. Accordingly, the former Wolf shareholders are expected to own approximately 31.45% of the Shares following the closing of the Transaction but prior to the closing of the Private Placement. No changes to management or to the board of directors of the Company are to occur with the Closing. No finder’s fees are payable in connection with the Transaction.
Private Placement
Concurrent with the closing of the Transaction, the Company intends to close a private placement of units of the Company (the “Units”) for minimum gross proceeds of $500,000, with each Unit comprised of one common share of the Company and one warrant, with each warrant exercisable into a common share of the Company for 3 years at an exercise price of $0.075 per share.
About Optimind Pharma
Optimind Pharma is an emerging provider of psychedelic therapies. From specializing in prescribing medical cannabis, ketamine-assisted treatment, and other psychedelic-enhanced psychotherapy modalities, Optimind Pharma helps individuals suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities.
Optimind exists to combine the power of psychedelic medicine with the science of psychology to provide legal psychedelic enhanced psychotherapy in a safe, controlled environment.